Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aptose Biosciences, Inc. - Common Shares (NQ:APTO)

1.710 UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aptose Biosciences, Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 Next >
Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the week with a breakdown of the biggest pre-market stock movers traders will want to keep a watch on Monday! 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Thursday
  Thursday saw 177 companies set new 52-week lows. 
Via Benzinga
Aptose Biosciences: Q2 Earnings Insights
Aptose Biosciences (NASDAQ:APTO) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
Why Aptevo Therapeutics Shares Are Trading Higher By More Than 100%; Here Are 28 Stocks Moving Premarket
Gainers 
Via Benzinga
Aptose Biosciences Establishes New At-The-Market Facility
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th
Data to be presented in poster at ASH Annual Meeting 
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib
From Aptose Biosciences, Inc.
Via GlobeNewswire
Why Lincoln National Shares Are Trading Lower By 31%? Here Are 72 Stocks Moving In Thursday's Session
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) gained 64% to $50.60. 
Via Benzinga
Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) shares jumped 242.8% to close at $105.72 on Thursday. The company announced a strategic plan to enter into the clean energy industry. 
Via Benzinga
Aptose Clinical Data to be Presented at the 2022 ASH Annual Meeting
Data for Tuspetinib (HM43239) and Luxeptinib Accepted for Poster Presentation 
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Reports Results for the Third Quarter 2022
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on Tuesday, November 1, 2022
From Aptose Biosciences, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 120 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday's session, 78 companies made new 52-week lows. 
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
FDA Grants Fast Track designation To Aptose Biosciences for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation
Aptose Biosciences Inc. (NASDAQ: APTO) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HM43239, an oral, myeloid kinome inhibitor, for the treatment of... 
Via Benzinga
38 Stocks Moving In Wednesday's Mid-Day Session
Gainers Allego N.V. (NYSE: ALLG) shares jumped 158.5% to $21.41 after the company announced the completion of its merger agreement with Spartan Acquisition Corp., which resulted... 
Via Benzinga
The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Rise and shine, trader! We're starting off the day with a breakdown of the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
32 Stocks Moving in Wednesday's Pre-Market Session
Gainers Zentek Ltd. (NASDAQ: ZTEK) rose 180.5% to $7.63 in pre-market trading after declining around 5% on Tuesday. Creative Realities Inc (NASDAQ: CREX) shares rose 52.6% to $1.... 
Via Benzinga
Aptose Biosciences: Q4 Earnings Insights
Aptose Biosciences (NASDAQ:APTO) reported its Q4 earnings results on Tuesday, March 22, 2022 at 04:01 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Scheduled For March 22, 2022
Companies Reporting Before The Bell • GDS Holdings (NASDAQ:GDS) is projected to report quarterly loss at $0.18 per share on revenue of $338.69 million. • HUYA (... 
Via Benzinga
Earnings Preview: Aptose Biosciences
Aptose Biosciences (NASDAQ:APTO) is set to give its latest quarterly earnings report on Tuesday, 2022-03-22. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Earnings Outlook For Aptose Biosciences
Aptose Biosciences (NASDAQ:APTO) is set to give its latest quarterly earnings report on Tuesday, 2022-03-22. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.